Caspofungin
- Generic Name
- Caspofungin
- Brand Names
- Cancidas, Cancidas (previously Caspofungin MSD)
- Drug Type
- Small Molecule
- Chemical Formula
- C52H88N10O15
- CAS Number
- 162808-62-0
- Unique Ingredient Identifier
- F0XDI6ZL63
- Background
Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
- Indication
For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
- Associated Conditions
- Abscess, Intra-Abdominal, Candidemia, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Oropharyngeal Candidiasis, Peritonitis, Pleural space infections
Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT01045798
Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients
- Conditions
- Invasive AspergillosisInvasive FusariosisInvasive Fungal Infections
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Universidade Federal do Rio de Janeiro
- Target Recruit Count
- 28
- Registration Number
- NCT00982540
- Locations
- 🇧🇷
Univ. Fed. Rio de Janeiro, Rio de Janeiro, RJ, Brazil
Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Gary E. Stein, Pharm.D.
- Target Recruit Count
- 21
- Registration Number
- NCT00839540
- Locations
- 🇺🇸
Sparrow Hospital, Lansing, Michigan, United States
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
- Conditions
- FungemiaNeutropeniaCandidiasis
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00806351
- Locations
- 🇸🇰
Pfizer Investigational Site, Kosice, Slovakia
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida
- Conditions
- CandidiasisFungemia
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT00805740
- Locations
- 🇨🇭
Pfizer Investigational Site, Geneve 14, Switzerland
Pharmacokinetics of Caspofungin in Burn Patients
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2011-12-16
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 2
- Registration Number
- NCT00748345
- Locations
- 🇫🇷
Cochin, Paris, France
A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 121
- Registration Number
- NCT00717860
Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 454
- Registration Number
- NCT00665639
- Locations
- 🇧🇷
7 Sites, Sao Paulo, Brazil
🇧🇷3 Sites, Belo Horizonte, Brazil
🇦🇷5 Sites, Buenos Aires, Argentina
A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 63
- Registration Number
- NCT00635648
Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)
- Conditions
- Fungal Infection
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 131
- Registration Number
- NCT00548080
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.